Department of Ophthalmology, Moran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA.
Jpn J Ophthalmol. 2012 Jul;56(4):289-306. doi: 10.1007/s10384-012-0147-2. Epub 2012 May 30.
Retinal photoreceptor degeneration takes many forms. Mutations in rhodopsin genes or disorders of the retinal pigment epithelium, defects in the adenosine triphosphate binding cassette transporter, ABCR gene defects, receptor tyrosine kinase defects, ciliopathies and transport defects, defects in both transducin and arrestin, defects in rod cyclic guanosine 3',5'-monophosphate phosphodiesterase, peripherin defects, defects in metabotropic glutamate receptors, synthetic enzymatic defects, defects in genes associated with signaling, and many more can all result in retinal degenerative disease like retinitis pigmentosa (RP) or RP-like disorders. Age-related macular degeneration (AMD) and AMD-like disorders are possibly due to a constellation of potential gene targets and gene/gene interactions, while other defects result in diabetic retinopathy or glaucoma. However, all of these insults as well as traumatic insults to the retina result in retinal remodeling. Retinal remodeling is a universal finding subsequent to retinal degenerative disease that results in deafferentation of the neural retina from photoreceptor input as downstream neuronal elements respond to loss of input with negative plasticity. This negative plasticity is not passive in the face of photoreceptor degeneration, with a phased revision of retinal structure and function found at the molecular, synaptic, cell, and tissue levels involving all cell classes in the retina, including neurons and glia. Retinal remodeling has direct implications for the rescue of vision loss through bionic or biological approaches, as circuit revision in the retina corrupts any potential surrogate photoreceptor input to a remnant neural retina. However, there are a number of potential opportunities for intervention that are revealed through the study of retinal remodeling, including therapies that are designed to slow down photoreceptor loss, interventions that are designed to limit or arrest remodeling events, and optogenetic approaches that target appropriate classes of neurons in the remnant neural retina.
视网膜光感受器变性有多种形式。视紫红质基因突变或视网膜色素上皮病变、三磷酸腺苷结合盒转运蛋白缺陷、ABCR 基因突变缺陷、受体酪氨酸激酶缺陷、纤毛病变和转运缺陷、转导蛋白和阻滞蛋白缺陷、杆状细胞环鸟苷酸 3',5'-单磷酸磷酸二酯酶缺陷、周边蛋白缺陷、代谢型谷氨酸受体缺陷、合成酶缺陷、与信号转导相关的基因突变缺陷等,都会导致视网膜变性疾病,如色素性视网膜炎(RP)或 RP 样疾病。年龄相关性黄斑变性(AMD)和 AMD 样疾病可能是由于一系列潜在的基因靶点和基因/基因相互作用所致,而其他缺陷则导致糖尿病性视网膜病变或青光眼。然而,所有这些损伤以及对视网膜的创伤性损伤都会导致视网膜重塑。视网膜重塑是视网膜变性疾病后的一种普遍发现,它导致神经视网膜与光感受器输入的去传入,因为下游神经元对输入的丧失会产生负性可塑性。在面对光感受器变性时,这种负性可塑性并不是被动的,在分子、突触、细胞和组织水平上会发现视网膜结构和功能的分阶段修正,涉及视网膜中的所有细胞类型,包括神经元和神经胶质细胞。视网膜重塑对视神经损伤的挽救具有直接意义,因为仿生或生物学方法会导致视网膜回路修正,从而破坏任何潜在的替代光感受器输入到残余的神经视网膜。然而,通过研究视网膜重塑,揭示了许多潜在的干预机会,包括旨在减缓光感受器丧失的治疗方法、旨在限制或阻止重塑事件的干预措施以及针对残余神经视网膜中适当神经元类别的光遗传学方法。